Foley Represents Nestle Skin Care and Galderma Against Truinject in Successful Institution of Two Inter Partes Reviews of Patents for Injection Training System
17 November 2020
Foley & Lardner is representing Galderma S.A. and Nestle Skin Health, Inc. in two IPR’s at the PTAB, challenging Truinject Corp.’s patents on automated detection of performance characteristics in an injection training system (U.S. Patent Nos. 10,290,231 and 10,290,232) following a district court complaint filed by Truinject based on the patents. On November 17, 2020, the PTAB granted institution of both IPRs, IPR2020-00935 and -00937 on all challenged claims on the requested grounds. Galderma S.A., formerly a subsidiary of Nestlé, is a global pharmaceutical company specializing in dermatological treatments and skin care products. The Foley team includes George Beck, Stephen B. Maebius, Chase Brill, and Kiri Lee Sharon.
People
Related News
06 May 2024
Press Releases
Foley Announces 2024 50-State Telehealth Survey
Foley & Lardner LLP today released the third edition of its 50-State Survey of Telehealth Insurance Laws, which provides a detailed report on each state’s telehealth commercial insurance coverage and payment/reimbursement laws and compares these laws before and after the Public Health Emergency (PHE).
01 May 2024
Press Releases
Foley Continues to Grow Its East Coast Transactions Practice, Adds M&A Partner Jeff Symons in New York
Foley & Lardner LLP announced today that it has strengthened its Transactions Practice with the addition of M&A partner Jeff Symons in New York.
30 April 2024
Press Releases
Foley Ventures Announces Fifth Fund to Invest in Firm Clients
Foley Ventures is pleased to announce Foley Ventures V, its latest venture fund launched in April 2024 to invest in companies and debt and equity fund clients.